Last reviewed · How we verify
NCT05388825
Pharmacodynamic Study of TPN171H Tablets in Patients With Mild to Moderate Erectile Dysfunction
Phase 2 trial testing TPN171H 2.5mg in Erectile Dysfunction in 84 participants. Completed in 17 February 2023.
4 January 2023
Quick facts
| Lead sponsor | Vigonvita Life Sciences |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 84 |
| Start date | 1 August 2022 |
| Primary completion | 4 January 2023 |
| Estimated completion | 17 February 2023 |
| Sites | 8 locations across China |
Drugs / interventions tested
- TPN171H 2.5mg
- TPN171H 5mg
- TPN171H 10mg
- Placebo 5mg — full drug profile →
- Placebo 10mg — full drug profile →
Conditions studied
- Erectile Dysfunction — all drugs for Erectile Dysfunction →
Sponsor
Vigonvita Life Sciences — full company profile →
Who can join
Adults 18 to 65, male only, with Erectile Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a randomized, double-blind, placebo-controlled, two-cohort, three-cycle crossover (at least a 5-day cleaning period per cycle), and a multicenter clinical trial design.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05388825
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Erectile Dysfunction
Currently open trials in the same condition.
- NCT07442396 — The Effectiveness of Exercise in the Treatment of Erectile Dysfunction and Premature Ejaculation · NA · recruiting
- NCT07366970 — Is There a Benefit From Addition of Exercise in Diabetic Patients With ED Who Complain Low Vitamin D? · NA · recruiting
- NCT06960746 — Changing Lifestyle in OSA Males Who Suffer Metabolic Syndrome and Impotence: Is There a Response? · NA · recruiting
- NCT06872866 — The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under · Phase 1 · recruiting
- NCT06805513 — Actual Use Trial of Tadalafil 5 mg · Phase 3 · recruiting
Other Vigonvita Life Sciences trials
Trials by the same sponsor.
- NCT07507838 — Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules · EARLY_PHASE1 · not yet recruiting
- NCT07302269 — Study of the Safety, Tolerability, Pharmacokinetics of VV261 Tablets in Chinese Healthy Volunteers · Phase 1 · recruiting
- NCT06749236 — A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension · Phase 1 · completed
- NCT06828887 — Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD · Phase 2 · recruiting
- NCT06504290 — Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119 · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05388825 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vigonvita Life Sciences
- Last refreshed: 23 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05388825.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing